10-Q: Cannabis Sativa Inc. Reports 35% Revenue Drop in Q1 2024 Amidst Increased Competition

Cannabis Sativa Inc. experienced a 35% decrease in revenue during the first quarter of 2024 compared to the same period last year, primarily due to heightened competition in the cannabis telemedicine market.

Summary

• Cannabis Sativa Inc.'s revenue for the three months ended March 31, 2024, was $225,131, a 35% decrease compared to $345,368 for the same period in 2023.
• The company's gross profit decreased by 47% to $126,113, down from $239,967 in the prior year.
• Total operating expenses decreased by 15% to $300,904, compared to $352,328 in the first quarter of 2023.
• The net loss from continuing operations was $174,791, compared to a net loss of $112,361 in the same period last year.
• The company's net loss for the period was $222,568, compared to a net loss of $500,101 for the same period in 2023.
• Cash used in operating activities was $24,744 for the three months ended March 31, 2024, and the company had $59,018 in cash on hand at the end of the quarter.
• The company has an accumulated deficit of $82,283,765 as of March 31, 2024.
• Management has identified material weaknesses in disclosure controls and procedures due to the small size of the accounting staff.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges, including a substantial revenue decrease, increased net loss, and material weaknesses in internal controls. The company's ability to continue as a going concern is also in question, leading to a negative sentiment.

Positives

• Cost of revenues as a percentage of sales decreased by 6% between the periods.
• Total operating expenses decreased by 15% due to cost reduction efforts.
• Advertising costs were reduced by taking a more focused approach to target markets.
• PrestoDoctor management salaries decreased in March 31, 2024.

Negatives

• Revenue decreased by 35% due to increased competition in the cannabis telemedicine industry.
• Gross profit decreased by 47% year-over-year.
• The company experienced a net loss of $222,568 for the quarter.
• The company has a significant accumulated deficit of $82,283,765.
• The company's cash on hand is only $59,018, which is not sufficient to meet immediate operational needs.
• Material weaknesses in disclosure controls and procedures were identified.

Risks

• The company faces significant competition in the cannabis telemedicine industry, which is impacting revenue.
• The company's ability to continue as a going concern is dependent on generating profitable operations or obtaining necessary financing.
• The company's small accounting staff may prevent adequate controls in the future.
• The company may need to raise capital through public or private offerings, which could dilute current shareholders.
• The company's current cash on hand is insufficient to meet immediate operational needs.

Future Outlook

The company may seek to raise money for working capital purposes through a public offering of its equity capital or through a private placement of equity capital or convertible debt. It will be important for the Company to be successful in its efforts to raise capital in this manner if it is going to be able to further its business plan in an aggressive manner. Raising capital in this manner will cause dilution to current shareholders.

Management Comments

• Management believes that material weaknesses in disclosure controls and procedures are due to the small size of the company's accounting staff.
• Management expects to increase the number of employees as the company grows, which will enable them to implement adequate segregation of duties within the internal control framework.

Industry Context

The decrease in revenue is primarily a result of the significant increase in competition for market share in the cannabis tele-medicine industry, indicating a challenging market environment for the company.

Comparison to Industry Standards

• The company's 35% revenue decrease is significant and suggests underperformance compared to industry averages, as many cannabis companies are experiencing growth, not contraction.
• The company's net loss of $222,568 and accumulated deficit of $82,283,765 are concerning and indicate financial instability compared to more established players in the cannabis sector.
• The identified material weaknesses in disclosure controls and procedures are a serious issue and are not typical for publicly traded companies, suggesting a need for significant improvements in internal controls.
• The company's reliance on related party transactions and convertible debt for financing is not uncommon for smaller cannabis companies, but the level of dependence and the terms of the debt may be less favorable than those of larger, more established competitors.

Corporate Governance

Legal Proceedings

• The company is not a party to any material legal proceedings, and, to the best of their knowledge, no such legal proceedings have been threatened against them.

Related Party Transactions

• The company has received funds from borrowings on notes payable and advances from related parties and officers of the company.
• The company has an outstanding loan in the amount of $4,000 to a director of the company.
• The company has a balance due from MJ Harvest, Inc., with whom the company plans to merge, of $75,054.

Stakeholder Impact

• Shareholders face potential dilution due to the company's need to raise capital.
• Employees may be impacted by the company's financial instability and potential restructuring.
• Customers may be affected by the company's ability to maintain service quality and pricing.
• Creditors face increased risk due to the company's financial challenges.

Next Steps

• The company needs to address the material weaknesses in disclosure controls and procedures.
• The company needs to secure additional funding to meet its operational needs.
• The company needs to improve its competitive position in the cannabis telemedicine market.

Key Dates

Keywords

Cannabis, Telemedicine, Revenue, Net Loss, Financial Results, Competition, Operating Expenses, Going Concern, Capital Raise, Disclosure Controls